The rapid evolution and dissemination of antibiotic resistance among bacterial pathogens
are outpacing the development of new antibiotics, but antivirulence agents provide an …

Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in
containing the global tuberculosis epidemic. Mycobacterium tuberculosis is intrinsically …

Tuberculosis (TB) remains the deadliest infectious disease, and the widely used Bacillus
Calmette–Guérin (BCG) vaccine fails to curb the epidemic. An improved vaccination strategy …

Antimicrobial resistance (AMR) and the associated morbidity and mortality due to bacterial
pathogens have been increasing globally to alarming levels. The World Health Organization …

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for
about 9.6 million new cases and 1.5 million deaths annually. The poorest and socially …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

Despite extensive global efforts in the fight against killer infectious diseases, they still cause
one in four deaths worldwide and are important causes of long-term functional disability …

The only licensed vaccine against tuberculosis (TB), bacille Calmette–Guérin (BCG),
protects against severe extrapulmonary forms of TB but is virtually ineffective against the …

WHO estimates that 9 million people developed active tuberculosis in 2013 and 1· 5 million
people died from it. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) …

Biomarkers for tuberculosis treatment outcome will assist in guiding individualized treatment
and evaluation of new therapies. To identify candidate biomarkers, RNA sequencing of …